TAIPEI, Taiwan: China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
Paxlovid, an oral medicine developed by New York-based drugmaker Pfizer, has been widely sought after in China since the country beganand a surge of infections started sweeping through the country. Although it is supposed to be prescribed by medical professionals, that has not stopped people scrambling to purchase it on their own through any means at their disposal - including buying generic Indian versions of the drug through the Internet, according to local media reports.
Health care policymakers can leverage bulk purchases to lower prices in negotiations with pharmaceutical companies that, in turn, can net a steady source of revenue.Related:
“China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.”
No surprise there it’s crap
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
China says talks to include Paxlovid in its health insurance drug list failThe antiviral drug is currently covered by China's broad healthcare insurance scheme under temporary measures. Read more at straitstimes.com. straits_times Not surprising why it failed. Lol Pfizer sucks
Source: STForeignDesk - 🏆 4. / 71 Read more »
Source: IndependentSG - 🏆 9. / 63 Read more »
Source: STForeignDesk - 🏆 4. / 71 Read more »
Source: straits_times - 🏆 5. / 69 Read more »
Source: STForeignDesk - 🏆 4. / 71 Read more »
Source: STForeignDesk - 🏆 4. / 71 Read more »